We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study to Assess the Efficacy and Safety of Raxone in LHON Patients (LEROS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02774005
Recruitment Status : Completed
First Posted : May 16, 2016
Last Update Posted : July 16, 2021
Information provided by (Responsible Party):
Santhera Pharmaceuticals

Brief Summary:
LEROS is an open-label interventional Phase IV study, designed to further assess the efficacy and safety of Raxone® in the long-term treatment of LHON patients.

Condition or disease Intervention/treatment Phase
Leber's Hereditary Optic Neuropathy (LHON) Drug: Idebenone Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 199 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment With Raxone® in Leber's Hereditary Optic Neuropathy (LHON)
Study Start Date : May 2016
Actual Primary Completion Date : March 29, 2021
Actual Study Completion Date : March 29, 2021

Arm Intervention/treatment
Experimental: Raxone Drug: Idebenone
Other Name: Raxone

Primary Outcome Measures :
  1. Proportion of eyes with clinically relevant recovery of visual acuity from Baseline [ Time Frame: 12 months ]
    Proportion of eyes with clinically relevant recovery of visual acuity (VA) from Baseline or in which Baseline VA better than 1.0 logMAR was maintained at Month 12 in patients treated with Raxone® ≤1 year after the onset of symptoms, compared to matching external natural history control group

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Impaired visual acuity in affected eyes due to LHON
  2. No explanation for visual loss besides LHON
  3. Age more or equal 12 years
  4. Onset of symptoms ≤5 years of Baseline
  5. Confirmation of either G11778A, G3460A or T14484C LHON mtDNA (for the ITT population, not required for enrolment)
  6. Written informed consent obtained from the patient
  7. Ability and willingness to comply with study procedures and visits
  8. Women of Childbearing Potential (WCBP) who have a negative urine or serum pregnancy test at Baseline visit and who are willing to use a highly effective contraceptive measure and maintain it until treatment discontinuation.

Exclusion Criteria:

  1. Patient has provided natural history data to the Case Record Survey (SNT-CRS-002)
  2. Any previous use of idebenone
  3. Any other cause of visual impairment (e.g. glaucoma, diabetic retinopathy, AIDS related visual impairment, cataract, macular degeneration, etc.) or any active ocular disorder (uveitis, infections, inflammatory retinal disease, thyroid eye disease, etc.)
  4. Known history of clinically significant elevations (greater than 3 times the upper limit of normal) of AST, ALT or creatinine
  5. Patient has a condition or is in a situation which, in an investigator's opinion may put the patient at significant risk, may confound study results or may interfere significantly with the patient's participation in the study
  6. Participation in another clinical trial of any investigational drug within 3 months prior to Baseline
  7. Hypersensitivity to the active substance or to any of the following excipients (as listed in section 6.1 of Raxone SmPC): Lactose monohydrate, Microcrystalline cellulose, Croscarmellose sodium, Povidone K25, Magnesium stearate, Colloidal silica, Macrogol 3350, Poly(vinyl alcohol), Talc, Titanium dioxide, Sunset yellow FCF (E110).
  8. Women who are pregnant or have a positive pregnancy test at Baseline visit
  9. Women who are breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02774005

Show Show 29 study locations
Sponsors and Collaborators
Santhera Pharmaceuticals
Layout table for additonal information
Responsible Party: Santhera Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02774005    
Other Study ID Numbers: SNT-IV-005
First Posted: May 16, 2016    Key Record Dates
Last Update Posted: July 16, 2021
Last Verified: July 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Optic Nerve Diseases
Optic Atrophy, Hereditary, Leber
Cranial Nerve Diseases
Nervous System Diseases
Eye Diseases
Optic Atrophies, Hereditary
Optic Atrophy
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Eye Diseases, Hereditary
Genetic Diseases, Inborn
Mitochondrial Diseases
Metabolic Diseases
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs